1-(2-hydroxyethyl)-dihydronicotinamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(2-hydroxyethyl)-dihydronicotinamide
• 英文别名: 1-(2-hydroxyethyl)-2H-pyridine-3-carboxamide
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: BCEXNKVZSGNIBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-碘乙醇 、 (S)-2-[3]pyridyl-pyrrolidine-1-carboxylic acid amide 生成 1-(2-hydroxyethyl)-3-carboxamidopyridinium iodide 、 1-(2-hydroxyethyl)-dihydronicotinamide
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] N'-NITROXYALKYLNICOTINAMIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] N'-NITROXYALKYLNICOTINAMIDES POUR LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：POLITECHNIKA LODZKA

  公开号：WO2010000673A1

  公开（公告）日：2010-01-07

  The invention relates to the novel N'-nitroxyalkylnicotinamide derivatives represented by the general formula (I) wherein R1 is C1C4 alkyl; R2 is hydrogen, C1-C4 alkyl, CH2OH or CH2ONO2; R3 is ONO2, CH2ONO2 or OH; provided that when R3 is OH, R2 is CH2ONO2; and X- is an organic or inorganic anion; as well as pharmaceutical compositions thereof and their use as a medicament, in particular, in the treatment of diseases of the cardiovascular system.

  这项发明涉及一种由通式（I）表示的新型N'-硝氧烷基烟酰胺衍生物，其中R1是C1-C4烷基；R2是氢、C1-C4烷基、CH2OH或CH2ONO2；R3是ONO2、CH2ONO2或OH；但当R3为OH时，R2为CH2ONO2；X-是有机或无机阴离子；以及其药物组合物及其作为药物的用途，特别是在治疗心血管系统疾病方面。
• N'-NITROXYALKYLNICOTINAMIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：Gebicki Jerzy

  公开号：US20110082177A1

  公开（公告）日：2011-04-07

  The invention relates to the novel N′-nitroxyalkylnicotinamide derivatives represented by the general formula I wherein R 1 is C 1 -C 4 alkyl; R 2 is hydrogen. C 1 -C 4 alkyl, CH 2 OH or CH 2 ONO 2 ; R 3 is ONO 2 , CH 2 ONO 2 or OH; provided that when R 3 is OH, R 2 is CH 2 ONO 2 ; and X − is an organic or inorganic anion; as well as pharmaceutical compositions thereof and their use as a medicament, in particular, in the treatment of diseases of the cardiovascular system.

  该发明涉及一种由通式I表示的新型N'-硝基烷基烟酰胺衍生物，其中R1为C1-C4烷基；R2为氢，C1-C4烷基，CH2OH或CH2ONO2；R3为ONO2，CH2ONO2或OH；但当R3为OH时，R2为CH2ONO2；X-为有机或无机阴离子；以及其药物组合物及其作为药物的用途，特别是在治疗心血管系统疾病方面。
• Therapeutic systems
  申请人：Enzacta R & D Limited

  公开号：US20030086933A1

  公开（公告）日：2003-05-08

  A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.

  该化合物包括一个靶细胞特异性部分和人类NAD（P）H：醌还原酶2（NQO2）或其变体或片段或融合物或衍生物，其对给定的前药具有与NQO2基本相同的活性，或者编码该NQO2或其变体或片段或融合物或衍生物的多核苷酸。一种重组多核苷酸，包括一个靶细胞特异性启动子与编码人类NAD（P）H：醌还原酶2（NQO2）或其变体或片段或融合物或衍生物的多核苷酸可操作地连接在一起，该NQO2或其变体或片段或融合物或衍生物对于给定的前药具有与NQO2基本相同的活性。这些化合物和多核苷酸在与合适的前药结合的方法中用于治疗患者。一种治疗表达NQO2的靶细胞的人类患者的方法，其中该方法包括向患者注射一种前药，该前药通过NQO2和烟酰胺核苷酸（还原）（NRH）或其类似物的作用被转化为基本上具有细胞毒性的药物。
• Human quinone reductase 2 conjugates for ADEPT and GDEPT
  申请人：ENZACTA R & D LIMITED

  公开号：EP1468698A2

  公开（公告）日：2004-10-20

  A compound having formula I for use in medicine and, in particular, for the treatment of mammalian tumours. A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug.

  一种具有式 I 的化合物，用于医药，特别是用于治疗哺乳动物肿瘤。 一种化合物，包括靶细胞特异性部分和人 NAD(P)H：醌还原酶 2 (NQO2)或其变体或片段或融合体或衍生物，其对给定原药的活性与 NQO2 基本相同；或编码所述 NQO2 或所述变体或片段或融合体或衍生物的多核苷酸。 一种重组多核苷酸，其包含与编码人NAD(P)H:醌还原酶2 (NQO2)或其变体或片段或融合体或衍生物的多核苷酸可操作地连接的靶细胞特异性启动子，该多核苷酸对给定原药具有与NQO2基本相同的活性。 这些化合物和多核苷酸在与合适的原药一起治疗患者的方法中是有用的。
• HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT
  申请人：ENZACTA R & D LIMITED

  公开号：EP0988059B1

  公开（公告）日：2005-12-07